Chimeric Financial Statements From 2010 to 2025
| CHMMF Stock | 0 0.00 0.00% |
Check Chimeric Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chimeric Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Chimeric financial statements analysis is a perfect complement when working with Chimeric Therapeutics Valuation or Volatility modules.
Chimeric |
Chimeric Therapeutics Limited Company Current Valuation Analysis
Chimeric Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Chimeric Therapeutics Current Valuation | 56.81 K |
Most of Chimeric Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chimeric Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Chimeric Therapeutics Limited has a Current Valuation of 56.81 K. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all United States stocks is notably lower than that of the firm.
Chimeric Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Chimeric Therapeutics's current stock value. Our valuation model uses many indicators to compare Chimeric Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Chimeric Therapeutics competition to find correlations between indicators driving Chimeric Therapeutics's intrinsic value. More Info.Chimeric Therapeutics Limited is rated second in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Chimeric Therapeutics' earnings, one of the primary drivers of an investment's value.About Chimeric Therapeutics Financial Statements
Chimeric Therapeutics stakeholders use historical fundamental indicators, such as Chimeric Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Chimeric Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Chimeric Therapeutics' assets and liabilities are reflected in the revenues and expenses on Chimeric Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Chimeric Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Chimeric Pink Sheet
Chimeric Therapeutics financial ratios help investors to determine whether Chimeric Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Chimeric with respect to the benefits of owning Chimeric Therapeutics security.